专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4955698A Opto-electronic indicating matrix, and indicating device provided therewith 失效
标题翻译：光电指示矩阵，以及指示装置
公开(公告)号：US4955698A
公开(公告)日：1990-09-11
申请号：US322781
申请日：1989-03-03
申请人： Peter Knoll , Winfried Konig , Rudiger Mock-Hecker , Clemens Gunther
发明人： Peter Knoll , Winfried Konig , Rudiger Mock-Hecker , Clemens Gunther
IPC分类号： G02F1/1343 , G09F9/30 , G09F9/35
CPC分类号： G02F1/134336 , G09F9/35
摘要： An opto-electronic indicating matrix comprises a plurality of row and column segments controllable in a multiplex operation, and means for electrically connecting the row and column segments and including a plurality of conductors arranged in regions between the row segments and inclined to a longitudinal axis of the row axis so as to extend parallel to one another in one plane. A preferable application of the matrix is in an indicator for travel guiding information in a power vehicle.
摘要翻译：光电指示矩阵包括可在多路复用操作中控制的多个行和列段，以及用于电连接行和列段并且包括布置在行段之间的区域中的多个导体并且倾斜于纵向轴线行轴线在一个平面中彼此平行地延伸。矩阵的优选应用在动力车辆中的旅行指导信息的指示器中。

2. 发明授权

US5858394A Agent for transdermal administration that contains gestodene esters 失效
标题翻译：含有孕甾酮酯的透皮给药剂
公开(公告)号：US5858394A
公开(公告)日：1999-01-12
申请号：US602808
申请日：1996-05-21
申请人： Ralph Lipp , Henry Laurent , Clemens Gunther , Jutta Riedl , Peter Esperling , Ulrich Tauber
发明人： Ralph Lipp , Henry Laurent , Clemens Gunther , Jutta Riedl , Peter Esperling , Ulrich Tauber
IPC分类号： A61K31/565 , A61P5/00 , C07J1/00 , A61F13/00 , A61K9/70
CPC分类号： A61K31/565
摘要： An agent for transdermal administration is described, which is characterized in that it contains gestodene esters with 1 to 20 carbon atoms in the ester radical optionally in combination with one or two estrogen(s).
摘要翻译： PCT No.PCT / EP94 / 02496 Sec。 371日期：1996年5月21日 102（e）日期1996年5月21日PCT 1994年7月24日PCT公布。公开号WO95 / 05827 日期1995年3月2日描述了一种用于经皮给药的试剂，其特征在于其含有酯基中具有1至20个碳原子的酯基酯，任选地与一个或两个雌激素组合。

3. 发明申请

US20060105030A1 Transdermal therapeutic system 审中-公开
公开(公告)号：US20060105030A1
公开(公告)日：2006-05-18
申请号：US11087754
申请日：2005-03-24
申请人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7053 , A61K31/48
摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

4. 发明授权

US5904931A Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide 失效
标题翻译：含有性类固醇和二甲基异山梨醇的透皮治疗系统
公开(公告)号：US5904931A
公开(公告)日：1999-05-18
申请号：US693050
申请日：1996-11-08
申请人： Ralph Lipp , Clemens Gunther , Jutta Riedl , Ulrich Tauber
发明人： Ralph Lipp , Clemens Gunther , Jutta Riedl , Ulrich Tauber
IPC分类号： A61F13/02 , A61K9/70 , A61K31/565 , A61K31/57 , A61K47/26 , A61P5/30 , A61P13/02 , A61P15/00 , A61P25/04 , A61P43/00 , A61F13/00
CPC分类号： A61K9/7053 , A61K31/565 , A61K31/57 , A61K47/26 , A61K9/7061 , A61K9/7069
摘要： Transdermal therapeutic systems that contain sex steroids and optionally penetration-enhancers and crystallization inhibitors are described, which are characterized in that they contain dimethyl isosorbide, with the exception of systems that contain active ingredient-containing, non-free-flowing gel phases or 3-keto-desogestrel.
摘要翻译： PCT No.PCT / EP95 / 00483 Sec。 371日期：1996年11月8日 102（e）日期1996年11月8日PCT提交1995年2月9日PCT公布。第WO95 / 22322号公报日本1995年8月24日描述了含有性类固醇和任选的渗透增强剂和结晶抑制剂的经皮治疗系统，其特征在于它们含有二甲基异山梨醇，除了含有活性成分的非自由流动凝胶相或3-酮去氧孕烯。

5. 发明申请

US20070243240A9 Transdermal therapeutic system 审中-公开
公开(公告)号：US20070243240A9
公开(公告)日：2007-10-18
申请号：US11087754
申请日：2005-03-24
申请人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Fred Windt-Hanke , Clemens Gunther , Reinhard Horowski , Johannes Tack , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： A61K9/70
CPC分类号： A61K9/7061 , A61K9/7053 , A61K31/48
摘要： The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the Restless Leg Syndrome and Periodic Limb Movement Disorder. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

6. 发明申请

US20050220855A1 Transdermal therapeutic system 审中-公开
公开(公告)号：US20050220855A1
公开(公告)日：2005-10-06
申请号：US11116279
申请日：2005-04-28
申请人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
发明人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer , Katalin Bostedt , Dirk Schenk
IPC分类号： C07D457/00 , A61K9/70 , A61K31/437 , A61K31/48 , A61K47/02 , A61K47/04 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/28 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61L15/58 , A61P5/08 , A61P5/24 , A61P13/02 , A61P13/10 , A61P15/00 , A61P15/08 , A61P15/14 , A61P25/02 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P43/00
CPC分类号： A61K9/7061 , A61K31/48
摘要： Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered. The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer.

7. 发明申请

US20050214353A1 Transdermal therapeutic system 审中-公开
标题翻译：透皮治疗系统
公开(公告)号：US20050214353A1
公开(公告)日：2005-09-29
申请号：US11116278
申请日：2005-04-28
申请人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer
发明人： Reinhard Horowski , Johannes Tack , Fred Windt-Hanke , Clemens Gunther , Adalbert Engfer
IPC分类号： C07D457/12 , A61K9/08 , A61K9/10 , A61K9/20 , A61K9/70 , A61K31/48 , A61K45/00 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/32 , A61K47/34 , A61K47/38 , A61P25/14 , A61P25/16
CPC分类号： A61K9/7061 , A61K31/48
摘要： Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome. The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.
摘要翻译： 1.一种透皮治疗系统（TTS），其包含含有至少一种具有活性成分和/或活性成分储存器的基质的药物层; 扩散阻挡层，其对所述活性成分是可渗透的并且设置在活性成分贮存器的皮肤侧上; 麦角灵衍生物或其盐作为制备用于在多巴胺治疗下获得和维持昼夜节律的药剂的活性成分。本发明涉及包含药用层的透皮治疗系统（TTS）的用途，所述药物层包含至少一种包含活性成分和/或活性成分储存器的基质和位于活性成分储存器的皮肤侧的扩散阻挡层对于产生用于治疗不宁腿综合症的方法，除了作为活性成分的麦角灵衍生物或与其酸的生理上相容的盐之外，活性成分可以渗透。本发明涉及由至少两个空间上分散的组合物组成的药剂形式的多巴胺激动剂的用途，其中一种是含有多巴胺能药物的透皮治疗系统（TTS），另一种是另外一种或多种用于口服和 /或肠胃外应用，其含有用于治疗多巴胺可治疗疾病的相同多巴胺能药物，其具有以下元件：a）连续施用TTS，b）在施用期间内，a）施用用于口服或非肠道给药的组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式